Bristol Myers Squibb (NYSE:BMY) said the FDA has accepted its application to have its CART T cell therapy Breyanzi approved for the treatment of certain patients with chronic lymphocytic leukemia, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback